About Endocrine Therapy
Endocrine therapy (or anti-estrogen therapy) is used to help lower the risk of recurrence for women diagnosed with hormone receptor-positive (HR+) breast cancer.
The most commonly used endocrine therapies are aromatase inhibitors (anastrozole, exemestane, letrozole) and Tamoxifen
Standard treatment is at least 5 years of endocrine therapy, but oncologists will sometimes recommend longer treatment to help reduce the risk of recurrence.
However, the majority of women DO NOT receive any benefit from extending endocrine therapy past year 5, but may still experience potential side effects and other health risks associated with treatment that can be significant.1-6
Breast Cancer Index helps identify which women are likely to benefit from extended endocrine therapy.
Help your patients with early-stage, HR+ breast cancer better understand their endocrine therapy options beyond 5 years
- Help them avoid debilitating side effects they may not need to endure
- Make them secure in their decision to continue with treatment if they are likely to benefit from extending endocrine therapy
You already lend a supportive ear and help them manage side effects. Now you can give them the tools to talk to their oncologist about their options.
Download a BCI BrochureReferences: 1. Davies C, et al. Lancet Oncol. 2013;381:805-816. 2. Gray R, et al. J Clin Oncol. 2013;31:(suppl; abstr 5).3. Jakesz R, et al. J Natl Cancer Inst. 2007;99:1845-1853. 4. Goss PE, et al. J Natl Cancer Inst. 2005;97:1262-1271. 5. Goss PE, et al. N Eng J Med. 2003;349(19):1793-1802. 6. Mamounas EP, et al. GS4-01 presented at SABCS; December 12, 2019.
